Bristol/Otsuka’s Abilify Approved To Treat Bipolar I Patients As Young As Age 10
This article was originally published in The Pink Sheet Daily
Executive Summary
Abilify now competes in the age 10-17 space with J&J’s Risperdal, approved in August.
You may also be interested in...
BMS’ Abilify Label Adds More Bipolars
Maintenance in pediatrics, teens made official by FDA.
BMS’ Abilify Label Adds More Bipolars
Maintenance in pediatrics, teens made official by FDA.
Otsuka, Justice Dept. Settle Charges For Off-Label Abilify Marketing
Japanese pharma agrees to pay $4 million to state and federal agencies.